|By PR Newswire||
|August 22, 2014 07:36 AM EDT||
PITTSBURGH, Aug. 22, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), which is the generic version of Upsher-Smith's Klor-Con®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. Mylan has begun shipping this product.
Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), had U.S. sales of approximately $135.05 million for the 12 months ending June 30, 2014, according to IMS Health.
Currently, Mylan has 294 ANDAs pending FDA approval representing $105.7 billion in annual brand sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $25.0 billion in annual brand sales, for the 12 months ending Dec. 31, 2013, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
Sep. 30, 2016 03:00 PM EDT Reads: 501
Sep. 30, 2016 03:00 PM EDT Reads: 3,657
Sep. 30, 2016 03:00 PM EDT Reads: 1,217
Sep. 30, 2016 03:00 PM EDT Reads: 3,002
Sep. 30, 2016 03:00 PM EDT Reads: 1,648
Sep. 30, 2016 02:45 PM EDT Reads: 2,631
Sep. 30, 2016 02:45 PM EDT Reads: 620
Sep. 30, 2016 02:30 PM EDT Reads: 2,462
Sep. 30, 2016 02:30 PM EDT Reads: 329
Sep. 30, 2016 02:30 PM EDT Reads: 5,225
Sep. 30, 2016 02:15 PM EDT Reads: 1,721
Sep. 30, 2016 02:15 PM EDT Reads: 1,154
Sep. 30, 2016 02:15 PM EDT Reads: 714
Sep. 30, 2016 02:00 PM EDT Reads: 3,570
Sep. 30, 2016 01:45 PM EDT Reads: 577